Literature DB >> 15014630

Selecting a Selective Serotonin Reuptake Inhibitor: Clinically Important Distinguishing Features.

Patricia A. Marken1, J Stuart Munro.   

Abstract

Selective serotonin reuptake inhibitors (SSRIs) are widely prescribed to treat depression. Although these drugs presumably have the same mechanism of action, they vary in several clinically important ways, including how long they remain in the body and the extent to which they interfere with the metabolism of other medications. This article reviews the pharmacologic differences among SSRIs and how these differences may affect various aspects of treatment, such as dosing, administration, and discontinuation. Understanding the distinct properties of SSRIs may help primary care physicians to design the most appropriate therapeutic plan for individual patients.

Entities:  

Year:  2000        PMID: 15014630      PMCID: PMC181142          DOI: 10.4088/pcc.v02n0602

Source DB:  PubMed          Journal:  Prim Care Companion J Clin Psychiatry        ISSN: 1523-5998


  49 in total

1.  The effect of sertraline on the pharmacokinetics of desipramine and imipramine.

Authors:  D L Kurtz; R F Bergstrom; M J Goldberg; B J Cerimele
Journal:  Clin Pharmacol Ther       Date:  1997-08       Impact factor: 6.875

2.  Functioning and utility for current health of patients with depression or chronic medical conditions in managed, primary care practices.

Authors:  K B Wells; C D Sherbourne
Journal:  Arch Gen Psychiatry       Date:  1999-10

3.  Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine.

Authors:  U Jeppesen; L F Gram; K Vistisen; S Loft; H E Poulsen; K Brøsen
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

4.  A study of the potential effect of sertraline on the pharmacokinetics and protein binding of tolbutamide.

Authors:  L M Tremaine; K D Wilner; S H Preskorn
Journal:  Clin Pharmacokinet       Date:  1997       Impact factor: 6.447

5.  Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers.

Authors:  J Alderman; S H Preskorn; D J Greenblatt; W Harrison; D Penenberg; J Allison; M Chung
Journal:  J Clin Psychopharmacol       Date:  1997-08       Impact factor: 3.153

6.  Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide.

Authors:  U Jeppesen; B B Rasmussen; K Brøsen
Journal:  Clin Pharmacol Ther       Date:  1997-09       Impact factor: 6.875

7.  Citalopram versus fluoxetine: a double-blind, controlled, multicentre, phase III trial in patients with unipolar major depression treated in general practice.

Authors:  M Patris; J M Bouchard; T Bougerol; J F Charbonnier; J F Chevalier; G Clerc; C Cyran; P Van Amerongen; O Lemming; H E Høpfner Petersen
Journal:  Int Clin Psychopharmacol       Date:  1996-06       Impact factor: 1.659

8.  Fluvoxamine is a potent inhibitor of cytochrome P4501A2.

Authors:  K Brøsen; E Skjelbo; B B Rasmussen; H E Poulsen; S Loft
Journal:  Biochem Pharmacol       Date:  1993-03-24       Impact factor: 5.858

9.  Increased carbamazepine plasma concentrations after fluoxetine coadministration.

Authors:  S R Grimsley; M W Jann; J G Carter; A P D'Mello; M J D'Souza
Journal:  Clin Pharmacol Ther       Date:  1991-07       Impact factor: 6.875

10.  Double-blind study of the efficacy and safety of sertraline versus fluoxetine in major depression.

Authors:  E Aguglia; M Casacchia; G B Cassano; C Faravelli; G Ferrari; P Giordano; P Pancheri; L Ravizza; M Trabucchi; F Bolino
Journal:  Int Clin Psychopharmacol       Date:  1993       Impact factor: 1.659

View more
  24 in total

1.  Dosing of Selective Serotonin Reuptake Inhibitors.

Authors:  Henry Chung
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2001-10

2.  Dr. Marken Replies.

Authors:  Patricia A. Marken
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2001-10

3.  Urinary selective serotonin reuptake inhibitors across critical windows of pregnancy establishment: a prospective cohort study of fecundability and pregnancy loss.

Authors:  Lindsey A Sjaarda; Jeannie G Radoc; Kerry S Flannagan; Sunni L Mumford; Keewan Kim; Neil J Perkins; Robert M Silver; Enrique F Schisterman
Journal:  Fertil Steril       Date:  2020-10-14       Impact factor: 7.329

4.  Exposure-based therapy changes amygdala and hippocampus resting-state functional connectivity in patients with posttraumatic stress disorder.

Authors:  Xi Zhu; Benjamin Suarez-Jimenez; Amit Lazarov; Liat Helpman; Santiago Papini; Ari Lowell; Ariel Durosky; Martin A Lindquist; John C Markowitz; Franklin Schneier; Tor D Wager; Yuval Neria
Journal:  Depress Anxiety       Date:  2018-09-10       Impact factor: 6.505

Review 5.  Symptom burden in heart failure: assessment, impact on outcomes, and management.

Authors:  Craig M Alpert; Michael A Smith; Scott L Hummel; Ellen K Hummel
Journal:  Heart Fail Rev       Date:  2017-01       Impact factor: 4.214

6.  Identifying the best treatment for young people with depression.

Authors:  Jeffrey R Strawn; John T Walkup
Journal:  Lancet Psychiatry       Date:  2020-07       Impact factor: 27.083

7.  Effects of Serotonin and Slow-Release 5-Hydroxytryptophan on Gastrointestinal Motility in a Mouse Model of Depression.

Authors:  Narek Israelyan; Andrew Del Colle; Zhishan Li; Yeji Park; Albert Xing; Jacob P R Jacobsen; Ruth Ann Luna; Dane D Jensen; Moneek Madra; Virginia Saurman; Ray Rahim; Rocco Latorre; Kimberly Law; William Carson; Nigel W Bunnett; Marc G Caron; Kara G Margolis
Journal:  Gastroenterology       Date:  2019-05-07       Impact factor: 22.682

Review 8.  Symptom management challenges in heart failure: pharmacotherapy considerations.

Authors:  Diana Stewart; Mary Lynn McPherson
Journal:  Heart Fail Rev       Date:  2017-09       Impact factor: 4.214

9.  Examining the Reversibility of Long-Term Behavioral Disruptions in Progeny of Maternal SSRI Exposure.

Authors:  Susan E Maloney; Shyam Akula; Michael A Rieger; Katherine B McCullough; Krystal Chandler; Adrian M Corbett; Audrey E McGowin; Joseph D Dougherty
Journal:  eNeuro       Date:  2018-07-09

10.  Effect of fluoxetine on the testes of adult albino rats and the possible protective role of curcumin.

Authors:  Basma Fathi Elsedawi; Youssef Hussein; Mohamed Ahmed Sabry; Joseph Amin Aziz
Journal:  Anat Sci Int       Date:  2020-10-14       Impact factor: 1.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.